A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Erlotinib
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 06 Sep 2016 Toxicity and efficacy results (n=22) published in the Journal of Thoracic Oncology.
- 12 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.